- Home
- IMAB
IMAB
I-MAB
as 10-04-2024 4:00pm EST
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 83.8M | IPO Year: | 2020 |
| Target Price: | $8.00 | AVG Volume (30 days): | 378.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.99 - $2.54 | Next Earning Date: | 08-28-2024 |
| Revenue: | $3,492,091 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest I-MAB News
IMAB Breaking Stock News: Dive into IMAB Ticker-Specific Updates for Smart Investing
MT Newswires
19 days ago
I-Mab Cancer Drug Trial Shows 'Encouraging' Topline Data
PR Newswire
19 days ago
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
PR Newswire
25 days ago
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
Simply Wall St.
a month ago
I-Mab First Half 2024 Earnings: US$0.19 loss per share (vs US$1.32 loss in 1H 2023)
PR Newswire
a month ago
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
PR Newswire
a month ago
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
PR Newswire
2 months ago
I-Mab to Release 1H 2024 Financial Results on August 28, 2024
PR Newswire
2 months ago
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
Compare IMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMAB I-MAB - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.